secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001326732-24-000002
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q4 2023 net loss $19.1M ($0.31 EPS); cash $697.4M; workforce cut ~10%
----------------------------------------------------------------------------

- Q4 2023 revenue $44.7M vs $21.6M YoY; full-year net loss $126.1M ($2.08) vs $55.2M ($0.93) in 2022.
- Cash and marketable securities $697.4M at Dec 31, 2023; guidance for end-2024 $475M-$525M, runway into 2027.
- Vudalimab in high-risk mCRPC showed 33% ORR (4/12) and PSA90 in 25%; plans to advance or decide by H1 2025.
- J&J milestones: $27.5M in Q4 2023; two new CD28 candidates selected; workforce cut ~10% in Jan 2024.
- Pausing cytokine programs XmAb564 (IL2-Fc) and XmAb662 (IL12-Fc) after data review; dosing first patient for XmAb541 in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000002/0001326732-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000002/xncr-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer